Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120229 | 0.80 | DPP4 (0.52) | HCRTR1DPP4 | |
| SCHEMBL376238 | 0.79 | CDK2 (0.38) | IRAK4HCRTR2HCRTR1 | |
| SCHEMBL17079782 | 0.77 | JAK3 (0.46) | JAK3BTKIRAK4SYKHCRTR2 | |
| SCHEMBL14956179 | 0.77 | JAK3 (0.46) | JAK3BTKIRAK4SYKHCRTR2 | |
| SCHEMBL14956530 | 0.77 | JAK3 (0.46) | JAK3BTKIRAK4SYKHCRTR2 | |
| SCHEMBL20583165 | 0.76 | KDR (0.40) | — | |
| SCHEMBL1919389 | 0.75 | IRAK4 (0.37) | IRAK4SYKHCRTR2HCRTR1DPP4 | |
| SCHEMBL14976231 | 0.75 | JAK3 (0.42) | JAK3BTKIRAK4SYK | |
| SCHEMBL377034 | 0.75 | ALDH1A1 (0.34) | IRAK4HCRTR2HCRTR1 | |
| SCHEMBL14961880 | 0.75 | JAK3 (0.58) | JAK3BTKIRAK4SYKHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | JAK3 1841/4885BTK 554/4885IRAK4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.